Risk factors

Transcode Therapeutics (RNAZ) risk factors

Item 1A of every Transcode Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open RNAZ in Gloomberb →
  • FY2025 10-K risk factors

    120 risks, 14 new, 12 dropped, 20 reworded since the prior year. Transcode Therapeutics acquired Polynoma in October 2025, adding Seviprotimut-L and new pipeline assets while taking on integration and financing risks.

    Filed Apr 15, 2026
  • FY2024 10-K risk factors

    118 risks. Transcode Therapeutics faces high risks from having no commercial products, substantial operating losses, and a critical need for near-term capital. Development of its lead oncology candidate, TTX-MC138, is at an early stage with substantial clinical and regulatory uncertainty.

    Filed Apr 15, 2025